3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
4
Phase 2
4
Phase 4
3
Phase 2/3
1
Phase 1/2
1
Status
Completed
3
Unknown
1
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Endocrine
2
NET
1
Conditions
Neuroendocrine Tumour With Carcinoid Symptoms
1
Neuroendocrine Tumors
1
Neoplasms
1
Acromegaly
1
Interventions
Zoledronic Acid
28
Saline Solution
26
Metformin
25
Dexamethasone
25
Cyclophosphamide
23
Cytarabine
22
Bupivacaine
20
Sodium Chloride
18
Vincristine
17
Methotrexate
17
Letrozole
17
Propofol
15
Morphine
15
Doxorubicin
15
Prednisolone
14
Docetaxel
14
Dexmedetomidine
14
Cisplatin
14
Bevacizumab
14
Oxycodone
13
Imiquimod
13
Fentanyl
13
Capecitabine
13
Rituximab
12
Mercaptopurine
12
Fluorouracil
12
Granulocyte Colony-Stimulating Factor
11
Everolimus
11
Asparaginase
11
Acetaminophen
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 4
×
Completed
×
lanreotide
×
Clear all
NCT00681187
2019-11-22
SAPHE
Ipsen
Phase 4
Completed
26 enrolled
18 charts
NCT02075606
2019-06-07
CALM-NET
Ipsen
Phase 4
Completed
50 enrolled
12 charts
NCT00627796
2008-03-03
ATG1line
Federico II University
Phase 4
Completed
27 enrolled